Monte Rosa Therapeutics, Inc.
GLUEHealthcareNASDAQBiotechnology · Last scanned Jun 1, 2026
Scan Results
Daily timeframeMonte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively. At a $1.67B market cap, Monte Rosa Therapeutics, Inc. ranks as a small-cap company within healthcare. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
Market Cap
$1.67B
Beta
1.62
P/E (TTM)
—
P/E (Fwd)
-10.86
EPS (TTM)
$-1.48
EPS (Fwd)
$-1.81
ROE
-32.6%
ROA
-16.4%
Cash
$666.2M
Total Debt
$39.1M
Free CF
-$77.2M
52W Change
338.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $666.2M in cash comfortably exceeding the $39.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$77.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -32.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Monte Rosa Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Monte Rosa Therapeutics, Inc. and its sector.